|
Teva Announces Approval Of Polyethylene Glycol 3350 NF For Oral Solution |
|
|
|
08 May 2006 |
JERUSALEM, Israel | May 07, 2006 | Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for their ANDA for Polyethylene Glycol 3350 NF for Oral Solution, 17 gram/scoopful. Teva’s Polyethylene Glycol 3350 NF for Oral Solution is the AB-rated generic equivalent of Braintree’s Miralax® for Oral Solution, a product indicated for the treatment of occasional constipation.
Total annual sales of Polyethylene Glycol 3350 NF for Oral Solution are approximately $153 million. Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Close to 90% of Teva’s sales are in North America and Europe.
SOURCE: Teva Pharmaceutical Industries, Ltd |
